Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bulumtatug fuvedotin
- Development stage
- Phase 3
- Lead developer
- Mabwell
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
Bulumtatug fuvedotin is an investigational antibody-drug conjugate (ADC) developed by Mabwell Biotech. It targets both tubulin and nectin-4, utilizing a monoclonal antibody linked to a cytotoxic payload via a cleavable linker. The mechanism of action involves inhibition of tubulin polymerization, leading to cell cycle arrest and apoptosis in target cells expressing nectin-4. This dual-targeting ADC is being developed primarily for oncology indications[6].
- Other names
- bulumtatug fuvedotin
02
Targets
PVRL4 (Nectin cell adhesion molecule 4)
Beyond the preview
Go deeper on bulumtatug fuvedotin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bulumtatug fuvedotin.